New COVID variant monitored as scientists study spread and symptoms.
Health officials are watching a newer version of the virus that causes COVID-19 after signs of steady growth in several parts of the world. The variant, known as BA.3.2 and nicknamed “Cicada,” has drawn attention because it carries a large number of genetic changes and has appeared in multiple countries after remaining mostly unnoticed for a long period. Public health agencies say the situation does not call for alarm but does require close tracking as scientists learn more about how the variant behaves.
The nickname comes from cicadas, insects known for staying hidden underground for years before emerging. Researchers say the comparison fits because this version of the virus was detected earlier but did not spread widely at first. Early records show the variant appearing internationally in late 2024, with later detections connected to travelers entering the United States in 2025. Since then, monitoring programs have picked up signs of gradual expansion.
Health agencies rely on several tools to follow new variants. One major method involves wastewater testing, which looks for traces of virus particles in sewage systems. Because infected people shed the virus even before symptoms appear, wastewater can reveal spread patterns early. Samples collected across dozens of states showed evidence of variant BA.3.2 in multiple regions, suggesting low-level circulation rather than a sudden outbreak. At the same time, other variants still account for a larger share of infections, meaning Cicada has not yet taken over as the dominant strain.
Scientists describe the variant as highly mutated because it contains dozens of genetic differences compared with earlier versions connected to the JN.1 lineage that has driven many recent cases. Mutations do not automatically mean a virus is more dangerous, but they can affect how easily it spreads or how well existing immunity works. Researchers are studying whether these changes help the variant avoid protection from prior infection or vaccination. Early comments from experts indicate that current vaccines may be less effective at preventing infection, though they are still expected to reduce severe illness and death.
Reports from other countries show that variant BA.3.2 has already reached notable levels in parts of Europe, where it has made up a sizable portion of analyzed cases in some areas. Even so, specialists caution that predicting whether it will become the main strain remains difficult. Virus trends often shift quickly depending on population immunity, seasonal patterns, and public behavior.
Symptoms linked to the variant appear similar to those seen with earlier COVID-19 infections. Common complaints include a runny or blocked nose, fatigue, headache, sore throat, coughing, and changes in smell or taste. Some patients have described intense throat pain, sometimes referred to informally as a “razorblade throat,” though doctors say overall severity does not appear higher than other circulating versions of the virus. Ongoing data collection will help confirm whether that assessment holds over time.
Medical guidance for those who become sick remains largely unchanged. Testing after symptoms begin helps confirm infection and reduces the risk of spreading illness to others. Health experts advise staying home while contagious, improving airflow indoors, and wearing a high-quality mask when contact with others cannot be avoided. Rest, hydration, and over-the-counter medications can help manage mild symptoms, while healthcare providers may recommend antiviral treatment for individuals at higher risk of complications.
Vaccination continues to play a role in protection, even when variants evolve. Updated boosters are designed to keep pace with changes in the virus, and researchers expect future formulations to adjust if BA.3.2 spreads further. Public health specialists note that lower vaccination rates and fewer prevention efforts can allow new variants more opportunity to circulate, which is why monitoring systems remain active even as emergency responses have eased.
The appearance of Cicada highlights how the virus continues to change years after the start of the pandemic. Experts say this ongoing evolution is normal for respiratory viruses and reinforces the need for steady surveillance rather than panic. Tracking new strains allows health systems to respond early, refine treatments, and guide public recommendations based on real-time evidence. While uncertainty remains, current information suggests the variant is another stage in the virus’s gradual adaptation rather than a return to the severe disruptions seen earlier in the pandemic.
Sources:
US ‘vulnerable’ to COVID variant ‘Cicada’. What to know about BA.3.2
New COVID variant called ‘Cicada’ identified. What are the symptoms, how prevalent is it?
Join the conversation!